Back to TAKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Gaucher Disease
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/26/2010
Vpriv
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Accelerated
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
REPLAGALPhase 3
Fabry Disease
Alogliptin and pioglitazonePhase 3
Type 2 Diabetes Mellitus
HYQVIAPhase 3
Primary Immunodeficiency Diseases (PID)
IGSC 20% infusionPhase 3
Primary Immunodeficiency Disease
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3
Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts